Sprint Bioscience AB (DE:5JA1)

FRANKFURT:5JA1

5JA1

Sprint Bioscience AB

RESEARCH TOOLSreports

Want to see DE:5JA1 full AI Analyst Report?

Sprint Bioscience AB (5JA1) Price & Analysis

0 Followers

5JA1 Stock Chart & Stats

€0.11

>-€0.01(-2.52%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-2.52%)

Day’s Range― - ―

52-Week Range€0.02 - €0.35

Previous CloseN/A

Volume0.00

Average Volume (3M)83.00

Market Cap

€30.28M

Enterprise Value€213.06M

Total Cash (Recent Filing)€126.70M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)1.5

Beta1.97

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding105,515,540

10 Day Avg. Volume250

30 Day Avg. Volume83

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€7.44M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt over 2021–2025 materially reduces refinancing risk and interest expense, giving management durable flexibility to allocate cash to discovery programs, business development or partnerships. A debt-free structure supports long-cycle R&D funding and resilience during biotech cycles.

Partnering/licensing ModelSprint's asset-light, out-licensing model monetizes early discovery through upfronts, research funding, milestones and royalties, shifting late-stage development and commercialization risk to larger partners. This scalable model can produce high-margin cash inflection points and aligns incentives with licensees.

2025 Profitability And Cash ImprovementThe 2025 inflection—material revenue growth, return to profitability and positive operating/free cash flow—demonstrates the firm's ability to convert discovery assets to cash. If sustained, this strengthens self-funding capacity, reduces dilution risk and improves long‑term partner negotiation leverage.

Bears Say

Revenue & Cash VolatilityRevenue and cash flows are highly lumpy due to milestone and partnership timing, which undermines forecast reliability and long-term planning. This volatility can force reactive financing, complicate multi‑year R&D investment decisions, and increase the firm's operational and strategic risk profile.

Historic Earnings InstabilityMulti-year losses prior to 2025 indicate profitability is not yet proven across cycles. A single profitable year can reflect timing of milestone receipts rather than sustained operating performance, so future R&D setbacks or delayed deals could rapidly reverse earnings and cash generation trends.

Equity/funding SensitivityA historically small or unstable equity base signals past funding sensitivity and reliance on external financing. This increases vulnerability to dilution or urgent capital raises if milestones miss, limiting strategic optionality and potentially constraining long‑term program advancement without partner funding.

5JA1 FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was €0.02 and its highest was €0.35 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is €30.28M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 12 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported €0.099 earnings per share for the quarter, beating the consensus estimate of N/A by €0.099.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of €0.099 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.614%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in DE:5JA1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.